004310.KS
Hyundai Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,680.00
−2.91%Year over year
Reported trailing growth
- Revenue
- +11.4%
- EBITDA
- +84.5%
- EBIT
- +250.3%
- EPS
- +209.7%
- Free cash flow
- +199.6%
- Operating cash flow
- +908.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- -9.0%
- EBIT
- -25.5%
- Net income
- -35.9%
- EPS
- -34.7%
- Free cash flow
- +65.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Aug 1, 2026